Skip to Content
Morningstar

Moderna Inc MRNA

Morningstar Rating
Unlock
Stock XNAS Rating as of
$106.18 −2.67 (2.45%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

Price vs Fair Value

View History
MRNA is trading at a 52% discount.
Price
$107.89
Fair Value
$467.00
Uncertainty
Very High
1-Star Price
$297.54
5-Star Price
$849.30
Economic Moat
Rxmvq
Capital Allocation
Dkgbqvd

Bulls Say, Bears Say

Bulls

The stellar efficacy and safety profile of Moderna's COVID-19 vaccine offered rapid validation of the firm's mRNA technology.

Bears

Moderna's Alexion partnership was terminated in 2017 after failure to find a safe but effective dose for the lead program, which could foreshadow difficulty finding a therapeutic window beyond low-dose vaccine programs.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if MRNA is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$108.85
Day Range
$103.52–108.23
52-Week Range
$62.55–142.79
Bid/Ask
$105.31 / $106.15
Market Cap
$40.65 Bil
Volume/Avg
2.8 Mil / 3.8 Mil

Key Statistics

Price/Earnings (Normalized)
39.52
Price/Sales
6.01
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
2.84%

Company Profile

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Core
Total Number of Employees
5,600
Website
https://www.modernatx.com

Competitors

Valuation

View More
Metric
MRNA
BNTX
PFE
Price/Earnings (Normalized)
 39.5227.7813.73
Price/Book Value
 2.930.941.60
Price/Sales
 6.015.172.44
Price/Cash Flow
 ——13.11
Price/Earnings
MRNA
BNTX
PFE

Financial Strength

Metric
MRNA
BNTX
PFE
Quick Ratio
 3.219.120.58
Current Ratio
 3.429.430.91
Interest Coverage
 −113.82—0.74
Quick Ratio
MRNA
BNTX
PFE

Profitability

Metric
MRNA
BNTX
PFE
Return on Assets (Normalized)
 −20.12%3.43%4.98%
Return on Equity (Normalized)
 −26.85%3.85%10.90%
Return on Invested Capital (Normalized)
 −26.68%2.43%7.28%
Return on Assets
MRNA
BNTX
PFE
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRYwqymflmzvDyxs$554.7 Bil
VRTX
Vertex Pharmaceuticals IncZzgkcdknCfwljgf$103.6 Bil
REGN
Regeneron Pharmaceuticals IncJjjgjqfdSvhfrqr$97.8 Bil
ARGX
argenx SE ADRKwzpdlctlQdpw$22.0 Bil
BNTX
BioNTech SE ADRPscryxnjgDwp$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncYvjnbwrcXztzyb$18.2 Bil
BMRN
Biomarin Pharmaceutical IncCpbpgffGkzbljk$17.3 Bil
RPRX
Royalty Pharma PLC Class APbxmpcmkbPzhxfx$12.5 Bil
INCY
Incyte CorpJnqrtynBzjgfc$11.5 Bil

Sponsor Center